Manuel C. Alves Aivado left the role of Director at Rein Therapeutics, Inc. As of November 14, 2026, Rein Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 19, 2026, naming 1 departure (Form 8-K, February 19, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Rein Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Rein Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-19. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Rein Therapeutics, Inc. files it.
Also on the record for Rein Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Lynwood Capital Management Inc. | 5% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by LYTTON LAURENCE W | 4.9% of the class | 5%+ stakes | Source |
| July 14, 2026 | Stake report, Schedule 13G/A, by Voss Capital, LP | 6.6% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G, by Lynwood Capital Management Inc. | 6.1% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by BIOS CAPITAL MANAGEMENT, LP | 9.99% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G, by Funicular Funds, LP | 6.7% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by LYTTON LAURENCE W | 5.8% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Voss Capital, LP | 17% of the class | 5%+ stakes | Source |
| September 26, 2025 | Stake report, Schedule 13G/A, by Voss Capital, LP | 11.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Rein Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Rein Therapeutics, Inc. and the records around it.
Rein Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Lynwood Capital Management Inc. also filed stake reports on 1 other company: Kazia Therapeutics Limited (Aug 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: ABEONA THERAPEUTICS INC. (Nov 2026), AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026)
- Voss Value Master Fund, LP also filed stake reports on 13 other companies: Five9, Inc. (Oct 2026), Cellebrite DI Ltd. (Aug 2026), ALTA EQUIPMENT GROUP INC. (Jul 2026)
Watch Rein Therapeutics, Inc.
Get an email when Rein Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rein Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Rein Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rein Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-19 | Out | Director | 8-K, 2026-02-19 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Manuel C. Alves Aivado, Director (filed 2026-02-19):
Dr. Aivado's decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
Who leads Rein Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Manuel C. Alves Aivado, departure reported (filed 2026-02-19). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Rein Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Rein Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Rein Therapeutics, Inc.Every change, in the filing's words
Departing: Manuel C. Alves Aivado, Director
On February 16, 2026, Manuel C. Alves Aivado, M.D., Ph.D., notified Rein Therapeutics, Inc. (the "Company") of his decision to resign as a member of the Board of Directors of the Company (the "Board"), effective immediately.
Tools for this story
Each opens in a new tab, filled in for Rein Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
